Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Interim CFO

Interim CEO

SVP, China General Manager

Chief Business Officer

Chief Executive Officer

Chief Financial Officer

See Remarks

China General Manager

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-09	Premium	back to issuer	Premium	Premium	Premium	Interim CFO
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	-
2024-02-15	Premium	acquired	Premium	Premium	Premium	-
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	Interim CEO
2024-02-15	Premium	acquired	Premium	Premium	Premium	Interim CEO
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	-
2024-02-15	Premium	acquired	Premium	Premium	Premium	-
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	-
2024-02-15	Premium	acquired	Premium	Premium	Premium	-
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	-
2024-02-15	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	sold	Premium	Premium	Premium	Interim CFO
2023-03-29	Premium	acquired	Premium	Premium	Premium	SVP, China General Manager
2023-03-29	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2023-03-29	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-03-29	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-01-03	Premium	sold	Premium	Premium	Premium	SVP, China General Manager
2022-08-18	Premium	bought	Premium	Premium	Premium	-
2022-05-26	Premium	bought	Premium	Premium	Premium	-
2022-05-25	Premium	bought	Premium	Premium	Premium	-
2022-05-24	Premium	bought	Premium	Premium	Premium	-
2022-05-23	Premium	bought	Premium	Premium	Premium	-
2022-05-04	Premium	acquired	Premium	Premium	Premium	See Remarks
2021-12-31	Premium	acquired	Premium	Premium	Premium	China General Manager
2021-12-29	Premium	acquired	Premium	Premium	Premium	-

LIAN - LianBio Stock Price, Fair Value and News

Latest Insider Trading transactions for LIAN